Alzheimer Disease Clinical Trials in Port Orange, Florida

7 studies are recruiting for alzheimer disease in Port Orange, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

   The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who c…

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Progressive Medical Research, Port Orange, Florida

   Locations

   252 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06937229 on ClinicalTrials.gov

2. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Progressive Medical Research, Port Orange, Florida

   Locations

   162 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07011732 on ClinicalTrials.gov

3. Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

   This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P…

   Stage

   Phase 2

   Ages

   55 to 80

   Site

   Progressive Medical Research, Port Orange, Florida

   Locations

   38 in total

   Run by

   Lighthouse Pharmaceuticals, Inc.

   See if you can join NCT06847321 on ClinicalTrials.gov

4. A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

   The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

   Stage

   Phase 4

   Ages

   50 and older

   Site

   Progressive Medical Research, Port Orange, Florida

   Locations

   14 in total

   Run by

   Alpha Cognition, Inc

   See if you can join NCT07633470 on ClinicalTrials.gov

5. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Local Institution - 1205, Port Orange, Florida

   Locations

   293 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

6. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   Progressive Medical Research, Port Orange, Florida

   Locations

   59 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov

7. A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

   The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). …

   Stage

   Phase 1

   Ages

   45 to 85

   Site

   Progressive Medical Research, Port Orange, Florida

   Locations

   13 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06657768 on ClinicalTrials.gov